期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胰高血糖素样肽-1及其受体激动剂对胰岛β细胞功能和数量的影响 被引量：6

原文传递
导出
摘要 胰岛β细胞功能的逐渐衰退在2型糖尿病的发生发展中起着重要作用。胰高血糖素样肽-1（GLP-1）是目前发现与2型糖尿病发生发展相关的肠促胰岛素，是“Incretin效应”的主要成分，可以增加正常人体内胰岛β细胞胰岛素的分泌，帮助调节整体葡萄糖代谢的动态平衡，并能促进胰岛β细胞增殖分化并减少其凋亡，对胰岛β细胞功能有一定的保护作用。
作者 黄旭 崔璨 张希尧 林淼
机构地区 [
出处 《临床内科杂志》 CAS 2013年第12期862-864,共3页 Journal of Clinical Internal Medicine
基金 国家自然科学基金资助项目（81100599）
关键词 GLP-1 GLP-1受体激动剂 胰岛Β细胞 2型糖尿病
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献22

  • 1H(o)jberg PV,Zander M,Vilsb(o)ll T. Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes[J].{H}DIABETOLOGIA,2008.632-640. 被引量：1
  • 2Park YJ,Ao Z,Kieffer TJ. The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets:implications in type 2 diabetes and islet transplantation[J].{H}DIABETOLOGIA,2013.508-519. 被引量：1
  • 3Butler AE,Janson J,Bonner-Weir S. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes[J].{H}DIABETES,2003.102-110. 被引量：1
  • 4Holst JJ,Seino Y. GLP-1 receptor agonists:targeting both hyperglycaemia and disease processes in diabetes[J].{H}Diabetes Research and Clinical Practice,2009.1-3. 被引量：1
  • 5Zhang F,Tang X,Cao H. Impaired secretion of total glucagon-like peptide-1 in people with im-paired fasting glucose combined impaired glucose tolerance[J].{H}International Journal of Medical Sciences,2012.574-581. 被引量：1
  • 6Edholm T,Cejvan K,Abdel-Halim SM. The incretin hormones GIP and GLP-1 in diabetic rats:effects on insulin secretion and small bowelmotility[J].{H}NEUROGASTROENTEROLOGY AND MOTILITY,2009.313-321. 被引量：1
  • 7Jacobo SM,Guerra ML,Hockerman GH. Cav1.2 and Cav1.3 are differentially coupled to glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion in the pancreatic β-cell line INS-1[J].{H}Journal of Pharmacology and Experimental Therapeutics,2009.724-732. 被引量：1
  • 8Madsbad S,Schmitz O,Ranstam J. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon like peptide 1 analog liraglutide (NN2211):a 12-week,double-blind,randomized,controlled trial[J].{H}DIABETES CARE,2004.1335-1342. 被引量：1
  • 9焦秀敏,武晋晓,张星光,吕肖锋.早期胰岛素泵强化治疗对初发2型糖尿病患者血胰高血糖素样肽-1的影响[J].临床内科杂志,2012,29(2):110-111. 被引量：6
  • 10Tourrel C,Bailbe D,Lacorne M. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon like peptide-1 or exendin-4[J].{H}DIABETES,2002.1443-1452. 被引量：1

二级参考文献7

  • 1Rossi MC,Nicolucci A.Liraglutide in type 2 diabetes:from pharmacological development to clinical practice.Acta Biomed,2009,80:93-101. 被引量：1
  • 2Kendall DM,Cuddihy RM,Bergensta RM.Clinical application of incretin-based therapy:therapeutic potential,patient selection and clinical use.Eur Intem Med,2009,20:S329-339. 被引量：1
  • 3Vilsboll T,Brock B,Perrild H,et al.Liraglutide,aonce daily human GLP-1 analogue,improves pancreatic B cell function and arginine stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus.DiabetMed,2008,25:152-156. 被引量：1
  • 4Garber A,Henry R,Ratner R,et al.Liraglutide versusglim epiridem on therapy for 2 diabetes (LEAD-3Mono):a randomized,52-week,phase 3,double-blind parallel-treatment trial.Lancet,2009,373:473-481. 被引量：1
  • 5Zinman B,Gerich J,Buse B,et al.Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolinedionedione in patients with type 2diabetes(LEAD-4Met +TZD).Diabetes Care,2009,32:1224-1230. 被引量：1
  • 6DoyleME,Egan JM.Mechanisms of action of glucagon-like peptide 1 in the pancreas.Phamacol Ther,2007,113:546-593. 被引量：1
  • 7Tibaduiza EC,Chen C,Beinbom M.A smallmolecule ligand of the glucagon-like peptide 1 receptor targets its amino-teminal homone binding domain.J Biol Chem,2001,276:37787-37793. 被引量：1

共引文献5

同被引文献56

  • 1闫哲,童南伟.《英国糖尿病医师协会与英国糖尿病学会对非糖尿病专科医师使用钠-葡萄糖共转运蛋白2抑制剂的联合声明与建议(2021版)》解读[J].临床内科杂志,2022,39(1):69-72. 被引量：1
  • 2董迎,张雯.T2DM患者合并NAFLD的危险因素分析[J].继续医学教育,2012,26(1):71-74. 被引量：1
  • 3贾连春,马立新,吴丽平,李志强.CT及B超用于脂肪肝临床诊断的比较研究[J].现代预防医学,2007,34(1):42-43. 被引量：18
  • 4陆冉英,钟南山.内科学[M].第7版.北京:人民卫生出版社,2008:170-179. 被引量：13
  • 5Bagger JI,Knop FK, Lund A, et al. Impaired regulation of the incretineffect in patients with type 2 diabetes [ J ]. J Clin Endocrinol Metab,2011,96(3) :737-745. 被引量：1
  • 6Bunck MC, Diamant M, Comer A, et al. Oen-year treatment with ex-enatide improves p-cell function, compared with insulin glargine, in met-formin-treated type 2 diabetic patients : a randomized, controlledtrial. Di-abetes Care,2009,32(5) :762-768. 被引量：1
  • 7Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide ( ex-endin-4) on glycemic control and weight over 30 weeks in patients withtype 2 diabetes treated with metformin and a sulfonylurea[ J] . DiabetesCare ,2005,28(5): 1083-1091. 被引量：1
  • 8Garber A,Henry R,Ratner R, et al. Liraglutide versus glimepiridemonotherapy for type 2 diabetes ( LEAD-3 Mono) : a randomised,52-week,phase III,double-blind,parallel-treatment trial[ J]. Lancet,2009,373(9662):473481. 被引量：1
  • 9PARKYJ,AO Z, KIEFER TJ, et al. The glucagon-likepeptide-1 receptor agonist exenatide restores impaired pro-isletamyloid polypeptide processing in cuhured human islets :implications in type2 diabetes and is let transplantation [J].Diabetologia, 2013,56(3) : 508-519. 被引量：1
  • 10ARMSTRONG MJ, HOULIHAN DD ’ ROWE IA, et al.Safety andefficacy of liraglutide in patients with type 2 diabetes andelevated liver enzymes : individual patient data meta -analysis ofthe LEAD program [ J]. Aliment Pharmacol Ther,2013,37 (2):234-242. 被引量：1

引证文献6

二级引证文献24

临床内科杂志
2013年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部